^
Association details:
| Biomarker: | MSLN expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | farletuzumab ecteribulin (MORAb-202) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers.
Published date:
05/25/2023
Excerpt:
Overall, responses to FZEC and MORAb-109 appeared to correlate with FRA and MSLN expression; importantly, some models with moderate to high target antigen expression showed deeper and more durable responses to FZEC and MORAb-109 compared to eribulin….Responses to FZEC and MORAb-109 correlated with FRA and MSLN expression, with equivalent or better activity compared to eribulin in target-positive PDX models of HGSOC, USC and OCCA.
DOI:
10.1200/JCO.2023.41.16_suppl.e17634
